Pulse Biosciences (NASDAQ:PLSE) Trading Up 5.2% – Time to Buy?

Pulse Biosciences, Inc. (NASDAQ:PLSE) shares rose 5.2% on Tuesday . The stock traded as high as $18.52 and last traded at $18.53. Approximately 11,517 shares were traded during trading, a decline of 90% from the average daily volume of 113,105 shares. The stock had previously closed at $17.61.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a research note on Thursday, January 2nd.

Pulse Biosciences Price Performance

The business’s 50 day moving average is $18.23 and its 200-day moving average is $17.58.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter in the prior year, the company posted ($0.19) earnings per share.

Insiders Place Their Bets

In related news, CEO Burke Thomas Barrett sold 50,000 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total transaction of $871,000.00. Following the sale, the chief executive officer now owns 63,172 shares of the company’s stock, valued at $1,100,456.24. This trade represents a 44.18 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Robert W. Duggan acquired 55,256 shares of Pulse Biosciences stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average price of $17.18 per share, for a total transaction of $949,298.08. Following the transaction, the director now directly owns 42,328,717 shares in the company, valued at $727,207,358.06. The trade was a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 71.50% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

Several large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp increased its stake in shares of Pulse Biosciences by 23.4% in the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after buying an additional 9,639 shares during the period. Rhumbline Advisers grew its holdings in Pulse Biosciences by 6.7% during the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock worth $288,000 after acquiring an additional 1,608 shares during the last quarter. Creative Planning increased its position in Pulse Biosciences by 113.9% in the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after acquiring an additional 11,667 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Pulse Biosciences by 193.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock valued at $2,598,000 after acquiring an additional 97,565 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Pulse Biosciences during the third quarter worth $588,000. 76.95% of the stock is currently owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.